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I examine the effect of pharmaceutical innovation on the functional status of nursing home residents
using cross-sectional, patient-level data from the 2004 National Nursing Home Survey.  This was the
first public-use survey of nursing homes that contains detailed information about medication use, and
it contains better data on functional status than previous surveys.
Residents using newer medications and a higher proportion of priority-review medications were more
able to perform all five activities of daily living (ADLs), controlling for age, sex, race, marital status,
veteran status, where the resident lived prior to admission, primary diagnosis at the time of admission,
up to 16 diagnoses at the time of the interview, sources of payment, and facility fixed effects.
The ability of nursing home residents to perform activities of daily living is positively related to the
number of “new” (post-1990) medications they consume, but unrelated to the number of old medications
they consume.  If 2004 nursing home residents had used only old medications, the fraction of residents
with all five ADL dependencies would have been 58%, instead of 50%.  During the period 1990-2004,
pharmaceutical innovation reduced the functional limitations of nursing home residents by between









There has been a significant decline over time in the functional limitations of older 
people in the United States, and probably worldwide. This finding has been confirmed using 
multiple datasets, multiple measures of functional disability, and multiple research 
methodologies.  For example, Costa (2000) found that functional limitation (difficulty walking, 
difficulty bending, paralysis, blindness in at least one eye, or deafness in at least one ear) in the 
United States fell at an average annual rate of 0.6% among men aged 50 to 74 from the early 
twentieth century to the early 1990s, and Manton, Gu, and Lamb (2006) found a significant rate 
of decline in the prevalence of chronic disability in the Medicare-enrolled population aged 65+ 
that accelerated from 1982 to 2004.  The recent decline in disability has occurred despite the 
considerable increase in obesity.
1 
A number of factors may have contributed to the long-run decline in disability.  It has 
been hypothesized that medical innovation in general, and pharmaceutical innovation in 
particular, have made important contributions to the decline in the functional limitations of older 
people.  Costa (2000) argued that “increased efficacy of medical care” was one of the two main 
factors that could account for the long-term decline in functional disability at older ages.
2  
Experts convened at a 2001 National Institute of Aging-National Bureau of Economic Research 
workshop on disability decline noted that “there have been many ‘high tech’ medical advances 
that have improved health” (Woodbury (2001)).  Three examples they cited were intensive 
treatment for heart disease, increased use of anti-inflammatory drugs for arthritis treatment, and 
“significant advances in both pharmacological and other treatment of mental illness.”  The 
experts agreed that “more research was recommended to better quantify the relative importance 
of [the] various factors” contributing to disability decline. 
In this paper, I will examine the effect of pharmaceutical innovation on the functional 
status of nursing home residents using cross-sectional, patient-level data from the 2004 National 
Nursing Home Survey (NNHS).  This was the first public-use survey of nursing homes that 
contains detailed information about medication use, and it contains better data on functional 
status than previous surveys.  In particular, I will investigate whether nursing home residents 
                                                            
1 The fraction of American adults that are obese (BMI greater than or equal to 30.0) increased from 22.9% in 1988-
94 to 34.3% in 2005-6.  http://www.cdc.gov/nchs/data/hestat/overweight/overweight_adult.htm#table1  
2 The second factor she cited is the decline in chronic disease rates. 2 
 
using newer drugs have higher functional status, controlling for multiple diagnoses and many 
other characteristics of residents and of the facilities where they reside.  About 1.5 million 
Americans resided in nursing homes in 2004.  Eighty-eight percent were 65 years and older; 45% 
were 85 years and older.
3   
The 2004 NNHS consisted of a two-stage design with a probability sample of 1,500 
nursing facilities in the first stage and up to 12 current residents from each facility in the second 
stage. This nationally representative sample survey was conducted by the Centers for Disease 
Control and Prevention’s National Center for Health Statistics from August 2004 through 
January 2005.  For 13,507 recipients, data were obtained on health status, medications taken, 
demographic characteristics, services received, and sources of payment.  Data for the survey 
were obtained through personal interviews with facility administrators and designated staff who 
used administrative records to answer questions about the facilities, staff, services and programs, 
and medical records to answer questions about the residents. 
The basic research design of the study is depicted in Figure 1.  The NNHS contains 
information about the ability of the resident to perform various activities of daily living (ADLs).  
For each activity, the resident’s ability is evaluated on an ordinal scale (from “independent” to 
“totally dependent”).  We will estimate ordered probit models
4 of the ability of an individual to 
perform activities of daily living.     
  The explanatory variables of primary interest are the characteristics of the medications 
used by the resident.
5  One important attribute is the mean vintage (FDA approval year) of 
medications used.  We hypothesize that the quality of new drugs tends to be higher than the 
quality of old drugs, and therefore that mean vintage is an indicator of the average quality of 
drugs consumed.  Drugs that received “priority-review” status from the FDA may also be of 
higher quality than “standard-review” drugs, conditional on FDA approval year.
6   As shown in 
Figure 1, we will control for a large set of nursing home resident attributes that are likely to 
                                                            
3 http://www.cdc.gov/nchs/data/nnhsd/Estimates/nnhs/Estimates_Demographics_Tables.pdf#Table01  
4 The probit procedure calculates maximum likelihood estimates of regression parameters and the natural (or 
threshold) response rate for quantal response data from biological assays or other discrete event data. Probit analysis 
developed from the need to analyze qualitative (dichotomous or polytomous) dependent variables within the 
regression framework. Ordinary least squares (OLS) regression is inadequate when the dependent variable is 
discrete. Probit or logit analyses are more appropriate in this case.  See Rodríguez (2010) for a discussion of the 
ordered probit model. 
5 The mean number of medications used by nursing home residents is nine. 
6 The “effective vintage” of a standard-review drug may be older than that of a priority-review drug. 3 
 
influence his or her functional status, including detailed information about diagnoses, 
demographic characteristics (age, sex, race, marital status, etc.), and sources of payment. 
We believe that heterogeneous pharmaceutical treatment of nursing home patients, 
controlling for their diagnoses, demographic characteristics, insurance coverage, facility, and 
other factors, is primarily due to physician practice variation.
7  Wennberg (2004) argues that 
“unwarranted [treatment] variation—variation not explained by illness, patient preference, or the 
dictates of evidence-based medicine—is a ubiquitous feature of U.S. health care.”  A large 
number of studies have documented the importance of unexplained variation in medical care in 
general and prescribing behavior in particular.  Much of this literature focuses on regional 
variation in medical treatment,
8 but a number of studies have shown that there is substantial 
treatment variation within narrowly-defined regions, health care organizations, and even 
facilities.  Dick et al (2011) analyzed data on 994 women who were diagnosed with Ductal 
Carcinoma In Situ from 1985 through 2000 in Monroe County (New York) and the Henry Ford 
Health System (Detroit, MI).  They found that “margin status and receipt of radiation therapy 
vary by surgeon,” and "the extent of variation [by surgeon] and its contribution to long-term 
health outcomes are troubling.”  Kralewski et al (1999) found that, even within a single 
Minneapolis/St. Paul HMO during 1990, there were “wide variations in individual physician 
practice styles” in the amount of resources used to manage uncomplicated hypertension.  
Ketcham et al (2007) found that “patients treated by solo physicians were less likely to receive 
cardiac catheterization and angioplasty within a day of admission and more likely to die than 
other patients in the same hospital, even after a number of patient and physician characteristics 
were taken into account” (emphasis added).  Data published by the New York State Department 
                                                            
7 Data collected by Levy et al (2006) from eight nursing homes indicated that the mean number of physicians who 
come to a facility is 15; the mean number of beds in the eight facilities was 212.  (The eight facilities were selected 
for case studies of physician practice models; no attempt was made to select a representative sample from which to 
draw statistical inferences.)  The mean number of prescribers in a facility is presumably greater than 15, since in 
some cases medications may also be prescribed by nursing home staff (medical directors) and advanced practice 
nurses.  The mean number of registered nurses in a nursing home is 8 
(http://www.cdc.gov/nchs/data/nnhsd/nursinghomefacilities2006.pdf). 
8 Some studies of regional variation have found no correlation across regions between measures of treatment 
intensity (e.g. per capita medical expenditure) and health outcomes.  But Lichtenberg (2011a, 2011b, 2011c) 
provides evidence based on longitudinal state-level data from both the U.S. and Germany that states that adopted 
medical innovations (new drugs and/or advanced imaging procedures) more rapidly had larger improvements in 
health (higher longevity growth and/or slower disability growth), controlling for other determinants of health. 4 
 
of Health (1998) indicate that the risk-adjusted mortality rates of patients receiving coronary 
artery bypass surgery varied considerably across surgeons operating within the same hospital. 
Health services researchers have identified a number of factors that explain some of the 
variation in individual physician practice styles, including physician gender, practice size, 
specialty, and membership in professional organizations. 
Physician gender.  DeSalvo et al (2000) reported “wide variation…in assignment
 of 
reappointment interval with mean return intervals…ranging from 2.2 to 20.5 weeks. Sex was a 
significant provider independent
 variable…Female
 providers assigned earlier reappointment 
intervals for their
 patients.”  Kuo et al (2011) examined the effect of physician characteristics on 
provision of recommended care practices for children with special health care needs among 
primary care physicians in Arkansas.  They found that female physicians spent more time with 
patients and were more likely to provide community referrals.   
Practice size.  Epstein et al (1983) studied the records of 351 hypertensive patients cared for by 
30 internists in group or solo private practice to investigate whether group size influences the 
number of tests ordered for ambulatory patients.  They found that patients of physicians who 
were members of large groups received twice as many tests as patients of physicians in small 
groups or in solo practice. These effects were independent of the patient's age and sex, the year 
the physician graduated from medical school, and the availability of testing machinery at the 
practice site.  Kuo et al (2011) found that solo and 2-person practice was associated with 
recommended care practices, including written care plan. 
Physician specialty.  Greenfield et al. (1992) found that cardiologists and endocrinologists had 
higher levels of resource utilization (hospitalizations, annual office visits, prescription drugs, and 
common tests and procedures) than physicians practicing family medicine and internal medicine, 
controlling for patient mix and other factors. 
Membership in professional organizations.  Chung et al (2011) found that Medicare beneficiaries 
who were treated by American Society for Surgery of the Hand member surgeons receive 
internal fixation for distal radius fractures (DRFs) at a significantly higher rate than do patients 
of other physicians. 5 
 
These factors explain some of the variation in individual physician practice styles, but 
most of the variation is unexplained.  For example, Kralewski et al (1999) found that “culture 




Functional status.  The survey obtained data on the ability of residents to perform the following 
five Activities of Daily Living (ADLs):  (1) transferring (to/from: bed, chair, wheelchair, 
standing position); (2) dressing; (3) eating; (4) using the toilet; and (5) bathing.  For each of these 
activities, the survey determined whether (1) the resident could perform the activity 
independently; (2) the resident requires supervision; (3) the resident requires limited assistance; 
(4) the resident requires extensive assistance; or (5) the resident is totally dependent.
9  Table 1 
shows the percent distribution of nursing home residents, according to type of assistance required 
with each activity of daily living.  It also shows the percent distribution of nursing home 
residents, by number of ADL dependencies (i.e., the number of activities for which the resident 
was not independent).  Half of residents had five ADL dependencies (i.e., they could not perform 
any of the five ADLs independently); 78% had 4 or more ADL dependencies.  Two-thirds of 
residents were able to eat independently or with supervision, but only 8% were able to bathe 
independently or with supervision. 
Medication attributes.  The survey also obtained data on all medications used by the resident.  
Nursing home residents tend to use many medications; the mean number of medications used is 
nine.  We identified the active ingredients of all of the medications used by each resident.  We 
used data provided by the FDA 
(http://www.fda.gov/Drugs/InformationOnDrugs/ucm079750.htm) to determine two attributes of 
each active ingredient: (1) the year in which the FDA first approved a product containing that 
active ingredient (we refer to this year as the “vintage” of the active ingredient); and (2) whether 
any products containing that active ingredient were approved on a priority-review (as opposed to 
standard-review) basis.  The FDA grants Priority Review designation to drugs that are believed 
to offer major advances in treatment, or provide a treatment where no adequate therapy exists, 
                                                            
9 Previous surveys (e.g. the 1999 NNHS) only reported whether or not the resident required at least some assistance. 6 
 
and Standard Review designation to drugs believed to offer at most, only minor improvement 
over existing marketed therapies.
10  Thus, although the vintage (FDA approval year) of a 
standard-review drug may be greater than that of an earlier drug, its “effective vintage” may not 
be greater. 
The NNHS provided data on N_RXia: the total number of medications used by resident i 
that contained active ingredient a (a=1,…,800).  From the Drugs@FDA database, we constructed 
the following variables: 
FDA_YEARa  = the year in which the FDA first approved a product containing active 
ingredient a 
POST1980a  = 1 if FDA_YEARa > 1980 
= 0 otherwise 
POST1990a  = 1 if FDA_YEARa > 1990 
= 0 otherwise 
PRIORITYa  = 1 if any products containing active ingredient a were approved on a priority-
review (as opposed to standard-review) basis 
= 0 otherwise 
 
We combined the NNHS medication data with the FDA ingredient attribute data to construct the 
following variables characterizing the distribution of medications used by each nursing home 
resident: 
 
VINTAGEi  = (a N_RXia FDA_YEARa) / a N_RXia = the (weighted) mean vintage of 
medications used by resident i 
POST1980%i  = (a N_RXia POST1980a) / a N_RXia = the fraction of medications used by 
resident i that contained active ingredients approved after 1980 
POST1990%i  = (a N_RXia POST1990a) / a N_RXia = the fraction of medications used by 
resident i that contained active ingredients approved after 1990 
PRIORITY%i  = (a N_RXia PRIORITYa) / a N_RXia = the fraction of medications used by 
resident i that contained active ingredients approved on a priority-review (as 
opposed to standard-review) basis 
N_RXi  = a N_RXia = the total number of medications used by resident i 
N_RX_NEWi  = a N_RXia POST1990a = the total number of “new” (post-1990) medications 
used by resident i 
N_RX_OLDi  = a N_RXia (1 - POST1990a) = the total number of “old” (pre-1991) 






We will estimate several models to investigate how the characteristics of medications 
used affects the functional status of nursing home residents.  The first model will be of the 
following form: 
HEALTHi =  VINTAGEi +  PRIORITY%i +  N_RXi +  Zi + i   (1) 
Six indicators of HEALTH will be used: the number of ADLs which the resident can perform 
independently (N_INDEP; N_INDEP = 0, 1,…, 5) and indicators of the extent of assistance 
required for each ADL.
11  The variable Z in eq. (1) represents a vector of a large number of other 
(non-medication-related) characteristics of the resident, whose elements will be described below.  
We hypothesize that  > 0: residents who use newer drugs will tend to be in better health, ceteris 
paribus.   We also hypothesize that  > 0: conditional on mean vintage, the greater the fraction of 
drugs that were priority-review drugs, the better the health of the consumer, since standard-
review drugs are similar to older drugs.  We are agnostic as to the sign of .  It would not be 
surprising if this coefficient were negative, i.e. if residents who consumed more medications 
were in worse health, since greater use of medical care (including prescription drugs) is often a 
marker for greater unobserved illness severity. 
  Eq. (1) is based on the implicit hypothesis that the effect of drug vintage on health status 
is linear.  This rather strong assumption can be relaxed by estimating the following alternative 
model: 
HEALTHi = 1 POST1980%i + 2 POST1990%i +  PRIORITY%i +  N_RXi +  Zi + i       (2) 
In this model, drugs approved before 1980 serve as the reference group.  1 is an estimate of the 
difference between the health effects of post-1980 drugs and pre-1981 drugs; 2 is an estimate of 
the difference between the health effects of post-1990 drugs and pre-1991 drugs; and (1 + 2) is 
an estimate of the difference between the health effects of post-1990 drugs and pre-1981 drugs. 
  In both of the preceding equations, the resident’s health is assumed to depend on the 
“quality” (vintage) and quantity of medications consumed in an additive fashion.  However, 
                                                            
11 These will be coded as follows: 4 = independent; 3 = supervision; 2 = limited assistance; 1 = extensive assistance; 
0 = total dependence. 8 
 
health may depend on the interaction between quality and quantity.
12  The following model 
allows for this interaction: 
HEALTHi = 1 N_RX_NEWi + 2 N_RX_OLDi +  PRIORITY%i +  Zi + i          (3) 
We hypothesize that 1 > 2: the effect on health of an increase in the number of new 
medications is larger than the effect on health of an increase in the number of old medications.
13 
Demographic variables.  We will control for single-year-of-age by sex, race, marital status, 
veteran status, and where the resident lived prior to admission. 
Diagnosis variables.  We will control for the primary diagnosis at the time of admission by 
including fixed primary-admission-diagnosis effects at the 2-digit ICD9 level.  We also control 
for up to 16 diagnoses at the time of the interview by including dummy variables for each 2-digit 
ICD9 disease.  If a resident had 5 diagnoses (comorbidities) at the time of the interview, five of 
these dummy variables would be equal to 1, and the remainder would be zero.   
Diseases of the circulatory system were the leading primary diagnoses among nursing 
home residents at admission (23.7%) and at the time of interview (25%).  Mental disorders were 
the second leading primary diagnoses among residents at admission (16.4%), as well as at the 
time of interview (21.9%). Fourteen percent of residents had a primary admission diagnosis for 
diseases of the nervous system and sense organs, and 16.5% had that primary diagnosis at the 
time of interview. 
Sources of payment.  We will include dummy variables for each of the following sources of 
payment: private health insurance; life care; Self/Private pay/out-of-pocket; Medicare (including 
Medicare HMO); Medicaid (including Medicaid HMO); Welfare or other government assistance; 
Department of Veterans Affairs; and Other payment source. 
Facility fixed effects.  All models will include 1125 facility fixed effects.  Due to the inclusion of 
these fixed effects, each nursing home resident is being compared with other residents of the 
same facility.  Inclusion of these fixed effects will correct for systematic biases in reporting by 
facility administrators, e.g. about functional limitations of residents. 
                                                            
12 Quality will matter more if the quantity is large. 
13 However, it might be the case that that 0 > 1 > 2. 9 
 
  Unfortunately, the NNHS does not provide information about other potential 
determinants of functional status, such as the resident’s income, wealth, or educational 
attainment.  However, these other potential determinants are likely to be controlled for, to an 
important extent, by factors included in the model, such as race, diagnoses, and sources of 
payment.  The facility fixed effects are also likely to control for a substantial amount of variation 
in socioeconomic status (SES), since SES is likely to play an important role in the “assignment” 
of residents to facilities. 
  Table 2 shows mean values of the medication attribute variables, by race (black vs. not 
black) of resident.  These data suggest that there is little or no correlation between medication 




  Table 3 shows descriptive statistics on medication attributes.  Table 4 shows the number 
of patients in the 2004 National Nursing Home Survey using prescription medicines, by class of 
drug. 
Table 5 shows the top 40 medications used by 2004 National Nursing Home Survey 
respondents, ranked by the number of residents using the medication.  The “FDA Approval 
Year” is the first year in which a product containing an ingredient was approved, according to 
the Drugs@FDA database.  Some drugs are certainly older than this calculation implies.  For 
example, according to the Merriam-Webster Dictionary, the first known use of the term “aspirin” 
was in 1899.
14  The Drugs@FDA database does not provide reliable estimates of the vintage of 
very old drugs (those that existed before the FDA was established in 1938).  It is likely that the 
variables POST1980% and POST1990% are measured more reliably than the VINTAGE 
variable. 
  Twenty-nine percent of 2004 nursing home residents were male, 8% were veterans, and 
10% were black.  Sources of payment are shown in Table 6.
15  
                                                            
14 http://www.merriam-webster.com/dictionary/aspirin  
15 There can be multiple payment sources.  Medicare's coverage of nursing home care is quite limited. Medicare 
covers up to 100 days of "skilled nursing care" per illness, but there are a number of requirements that must be met 
before the nursing home stay will be covered.  http://seniorjournal.com/NEWS/Medicare/2008/8-01-18-
SenCitNeed2Know.htm  A life-care fee or “founder's fee” is paid either monthly or as a lump sum under an 




Estimates of selected coefficients from the first model of the functional status of nursing 
home residents (eq. (1)) are shown in Table 7.  As noted earlier, all models include dummy 
variables for single-year-of-age by sex, race, marital status, veteran status, where the resident 
lived prior to admission, primary diagnosis at the time of admission, up to 16 diagnoses at the 
time of the interview, sources of payment, and facility fixed effects. 
The dependent variable of the first model (model 1a) in Table 7 is the number of ADLs 
the resident could perform independently.  As we hypothesized, the coefficients on VINTAGE 
and PRIORITY% are both positive and highly significant.  Residents using newer medications, 
and medications approved on a priority-review basis, were able to perform more activities of 
daily living independently, ceteris paribus.  Recall that the FDA considers standard-review drugs 
(those not granted priority review) to be therapeutically similar to previously-approved drugs.  
The fact that the ratio of the PRIORITY% coefficient to the VINTAGE coefficient is 22.6 
suggests that standard-review drugs are similar to drugs approved 22.6 years earlier, on average.   
  The coefficient on the number of medications consumed (N_RX) is also positive and 
highly significant: residents consuming more medications were able to perform more activities of 
daily living independently.  This is somewhat surprising since, as noted earlier, greater use of 
medical care (including prescription drugs) is often a marker for greater unobserved illness 
severity. 
  In the remaining five models (models 1b-1f) of Table 7, the dependent variables are 
indexes of the ability of residents to perform each of the five activities of daily living 
(transferring, dressing, etc.).  In all five models, all three of the medication coefficients are 
positive and highly significant.  Residents using newer medications, a higher proportion of 
priority-review medications, and more medications were more able to perform all five activities 
of daily living. 
  The estimates in Table 7 are from models that include facility fixed effects.  We also 
estimated models that included a set of observable facility characteristics (dummy variables for 11 
 
nursing home ownership type, bedsize, and metropolitan area status
16) instead of facility fixed 
effects, and models that included neither facility characteristics nor facility fixed effects.  
Estimates of the VINTAGE and PRIORITY% coefficients from these models and models with 
facility fixed effects are shown in Table 8.  In models 1-3 of Table 8, the dependent variable is 
the number of ADLs the resident could perform independently.  Model 1 includes neither facility 
characteristics nor facility fixed effects (but all of the other covariates enumerated above).  
Model 2 includes facility characteristics, and model 3 includes facility fixed effects.  Both the 
VINTAGE and the PRIORITY% coefficients are positive and highly significant in all three 
models.  The estimates of models 1 and 2 are quite similar: controlling for facility characteristics 
has almost no effect on these coefficients.  But controlling for facility fixed effects significantly 
increases the magnitude of both coefficients: the VINTAGE coefficient is 55% larger in model 3 
than it is in model 1, and the PRIORITY% coefficient is 34% larger.  Models 4-18 of Table 8 
show that we obtain similar results when we analyze the other dependent variables: the 
VINTAGE and PRIORITY% coefficients are positive and highly significant when we don’t 
control for facility fixed effects (whether or not we control for facility characteristics), but are 
larger when we control for facility fixed effects.  Since the facility fixed effects are likely to 
control for important determinants of measured functional status (e.g. the socioeconomic status 
of residents, unmeasured quality of healthcare providers, and biases in facility survey responses), 
we believe that models including facility fixed effects are the most reliable, and these fixed 
effects will be included in the models discussed in the remainder of this article. 
  Table 9 presents estimates of eq. (2), in which the VINTAGE variable is replaced by 
POST1980% and POST1990%.  In all six models, the coefficients on all four medication 
variables are positive and significant.  These estimates indicate that post-1980 medications 
reduce functional limitations more than pre-1981 medications, and that post-1990 medications 
reduce functional limitations more than pre-1991 medications.  Moreover, the difference 
between the effects of post-1990 medications and medications approved in the 1980s is larger 
than the difference between medications approved in the 1980s and medications approved before 
1981. 
                                                            
16 There are two ownership status categories (for-profit vs. all others (private and gov't not-for-profit)), four bedsize 
categories (3-49 beds, 50-99 beds, 100-199 beds, and 200+ beds), and three metropolitan area status categories 
(metropolitan, micropolitan, and neither). 12 
 
Table 10 presents estimates of eq. (3), in which there are three medication variables: the 
number of “new” (post-1990) medications (N_RX_NEW), the number of “old” (pre-1991) 
medications (N_RX_OLD), and the fraction of (all) medications that were granted priority-
review (PRIORITY%).  In all six models, the coefficient on N_RX_NEW is positive and highly 
significant. The coefficient on N_RX_OLD is insignificant in four of the six models.  It is 
positive and significant in only one model (model 3d, ability to eat), and in this case, it is only 
1/7 as large as the coefficient on N_RX_NEW.  This signifies that, in general, the ability of 
nursing home residents to perform activities of daily living is positively related to the number of 
new medications they consume, but unrelated to the number of old medications they consume.  
The positive coefficients on the total number of medications (N_RX) in eqs. (1) and (2) (Tables 
3 and 4) was solely attributable to new medications. 
All of the estimates reported so far have attempted to assess the impact of pharmaceutical 
innovation in general on the functional limitations of nursing home residents.  Assessing the 
impact of specific types of pharmaceutical innovation (i.e., innovation in specific classes of 
drugs) is also worthwhile.  If we had a much larger sample of patients, we could accomplish this 
by including characteristics (e.g. vintage) of multiple classes of drugs in a single model.  But 
most patients take drugs in only a few classes, so including characteristics of multiple classes of 
drugs in a single model would severely limit our sample size.  Therefore, we have estimated 
versions of eq. (3) separately for the five most highly utilized drug classes shown in Table 4.   
These estimates are shown in Table 11.
17  We report estimates of six models in this table.  
In all of these models, the dependent variable is the number of ADLs the resident could perform 
independently, and the explanatory variables are: the patient’s number of post-1980 medications 
within the drug class, the patient’s number of pre-1981 medications within the drug class, and 
the fraction of the patient’s medications within the drug class that were granted priority review.  
Model 1 in Table 11 shows estimates based on data on all medications.  These estimates are 
consistent with the estimates presented in Table 10 (which defined new drugs as post-1990 
drugs).  Models 2-6 in Table 11 show estimates based on each of the five drug classes.  In 3 out 
of 5 classes (metabolic/nutrients, cardiovascular-renal drugs, and central nervous system drugs), 
                                                            
17 The number of observations for each drug class shown in Table 11 is lower than the number of patients using each 
drug class shown in Table 4 because the FDA approval years of some drugs could not be determined. 13 
 
the coefficient on the number of post-1980 medications is positive and highly significant, and the 
coefficient on the number of pre-1981 medications is not significant at the 5% level.  In a fourth 
class (gastrointestinal agents), the coefficient on the number of post-1980 medications is 
insignificant, and the coefficient on the number of pre-1981 medications is negative and  
significant; the difference between the two coefficients is positive and presumably significant
18 
(as it is in models 2, 3, and 5).  In the fifth class (relief of pain drugs), the coefficient on the 
number of post-1980 medications is again larger than the coefficient on the number of pre-1981 
medications, but the difference appears to be insignificant.  These results indicate that the 
estimates presented in Tables 7-10 do not merely reflect the impact of innovation in a small 
minority of drug classes. 
Now I will use the estimates in Table 10 to estimate how much higher the functional 
limitations of 2004 nursing home residents would have been if only pre-1991 medications had 
been used.  As noted earlier, in 2004 the mean values of N_RX_NEW and N_RX_OLD were 
3.63 and 5.51, respectively, and the mean value of N_RX was 9.14 (= 3.63 + 5.51).  Suppose that 
2004 nursing home residents had consumed the same number of medications, but that none of 
those medications were post-1990 medications: N_RX_NEW = 0 and N_RX_OLD = 9.14.   
Fourteen years earlier (in 1990), none of the medications could have been post-1990 
medications.  The coefficients on N_RX_NEW and N_RX_OLD in Table 10 allow us to 
estimate how much higher the functional limitations of 2004 nursing home residents would have 
been had they used zero new medications and 9.14 old medications instead of 3.63 new 
medications and 5.51 old medications.  The predicted probability of being totally dependent is 
prob_depend_pred = F[F
-1(prob_depend_actual) + 3.63 (1 – 2)] 
where prob_depend_actual = the actual probability of being totally dependent (shown in Table 
1); 1 = the coefficient on N_RX_NEW in eq. (3); 2 = the coefficient on N_RX_OLD in eq. 
(3); F( ) is the standard normal cumulative distribution; and F
-1( ) is the inverse of the standard 
normal cumulative distribution. 
  The results of these calculations are shown in Figure 2.  The estimates imply that the 
functional limitations of 2004 nursing home residents would have been considerably greater if 
only pre-1991 medications had been used.  For example, we estimate that 33% of residents 
                                                            
18 The software we use (the SAS Probit procedure) does not allow us to perform tests of the significance of 
differences between parameter estimates. 14 
 
would have been totally dependent to get dressed, instead of 25% of residents.
19  Since only pre-
1991 medications were used in 1990, (1/14) * ln(prob_depend_actual/prob_depend_pred) is an 
estimate of the average annual rate of decline of functional limitation due to pharmaceutical 
innovation during the period 1990-2004.  These estimates, by ADL, are shown in Table 12. 
During the period 1990-2004, pharmaceutical innovation is estimated to have reduced the 
functional limitations of nursing home residents by between 1.2% and 2.1% per year. 
Summary and conclusions 
There has been a significant decline over time in the functional limitations of older 
people in the United States, and probably worldwide.  Previous investigators have hypothesized 
that medical innovation in general, and pharmaceutical innovation in particular, has made 
important contributions to the decline in the functional limitations of older people.  In this paper, 
I have examined the effect of pharmaceutical innovation on the functional status of nursing home 
residents using cross-sectional, patient-level data from the 2004 National Nursing Home Survey.  
This was the first public-use survey of nursing homes that contains detailed information about 
medication use, and it contains better data on functional status than previous surveys. 
I found that residents using newer medications and a higher proportion of priority-review 
medications were more able to perform all five activities of daily living, controlling for age, sex, 
race, marital status, veteran status, where the resident lived prior to admission, primary diagnosis 
at the time of admission, up to 16 diagnoses at the time of the interview, sources of payment, and 
facility fixed effects.   
The ability of nursing home residents to perform activities of daily living is positively 
related to the number of “new” (post-1990) medications they consume, but unrelated to the 
number of old medications they consume.  We estimated how much higher the functional 
limitations of 2004 nursing home residents would have been had they used old medications 
instead of new medications.  We estimate that the fraction of nursing home residents with all five 
ADL dependencies (number of activities for which the resident is not independent) would have 
been 58%, instead of 50%.  During the period 1990-2004, pharmaceutical innovation is 
                                                            
19 We also estimate that the fraction of nursing home residents with all five ADL dependencies (number of activities 
for which the resident is not independent) would have been 58%, instead of 50%. 15 
 
estimated to have reduced the functional limitations of nursing home residents by between 1.2% 
and 2.1% per year. 
Unfortunately, the NNHS does not provide information about some potential 
determinants of functional status, such as the resident’s income, wealth, or educational 
attainment.  However, these other potential determinants are likely to be controlled for, to an 
important extent, by factors included in the model, such as race, diagnoses, and sources of 
payment.  The facility fixed effects are also likely to control for a substantial amount of variation 
in socioeconomic status (SES), since SES is likely to play an important role in the “assignment” 
of residents to facilities.  Also, analysis of data by race suggested that there is little or no 
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  Mean vintage (FDA approval year) 
of rx’s 
  % of rx’s that are for priority-review 
drugs 
  Number of rx’s for “new” drugs 
  Number of rx’s for “old” drugs 
Patient diagnoses 
  Current primary diagnosis 
  Current secondary diagnoses (up to 
16) 
Demographic variables 
  Age 
  Gender 
  Marital status 
  Veteran status 
  Race 
  Where staying before entering this 
facility  
  Sources of payment (Private 
insurance, Medicare, Medicaid, 
Self-pay, Welfare, VA) 
Indicators of functional status 
Ability to perform Activities of Daily 
Living (ADLs):   
  transferring (to/from: bed, chair, 
wheelchair, standing position) 
  dressing 
  eating 
  using the toilet 
  bathing 
 
For each of these activities, is the 
subject’s self-performance: 
  independent 
  requires supervision 
  requires limited assistance 
  requires extensive assistance 
  is totally dependent 
Facility fixed effects Extent of assistance required transfer dress eat toilet bath
Independent 22% 11% 44% 18% 2%
Supervision 7% 7% 23% 6% 6%
Limited assistance 20% 22% 10% 17% 9%
Extensive assistance 28% 35% 9% 28% 46%
Total dependence 22% 25% 15% 31% 37%
TOTAL 100% 100% 100% 100% 100%
Number of ADL dependencies 
(number of activities for which 
















Percent distribution of nursing home residents, according to extent of assistance required 
with activities of daily livingBlack or African American 
(N=1406)
Not Black or African American 
(N=12,101)
weighted mean vintage of 
medications used (VINTAGE)
1980.3 1980.5
fraction of medications used 
that contained active 
ingredients approved after 1980 
(POST1980%)
59% 57%
fraction of medications used 
that contained active 
ingredients approved after 1990 
(POST1990%)
39% 40%
fraction of medications used 
that contained active 
ingredients approved on a 





Mean values of the medication attribute variables, by race (black vs. not black) of residentmean std. dev. minimum maximum
weighted mean vintage 
of medications used 
(VINTAGE)
1980.47 7.26 1911 2006
fraction of medications 
used that contained 
active ingredients 
approved on a priority-
review (as opposed to 
standard-review) basis 
(PRIORITY%)
49% 20% 0% 100%
fraction of medications 
used that contained 
active ingredients 
approved after 1980 
(POST1980%)
57% 22% 0% 100%
fraction of medications 
used that contained 
active ingredients 
approved after 1990 
(POST1990%)
40% 22% 0% 100%
the total number of 
medications used 
(N_RX)
9.02 4.16 0 30




3.63 2.33 0 16




5.51 3.01 0 21
Table 3
Descriptive statistics on medication attributesNational Drug Code Directory drug class Number of patients
9 METABOLIC/NUTRIENTS 10,015
5 CARDIOVASCULAR-RENAL DRUGS 9,994
8 GASTROINTESTINAL AGENTS 9,635
6 CENTRAL NERVOUS SYSTEM 9,322
17 RELIEF OF PAIN 8,752
10 HORMONES/HORMONAL MECHANISMS 5,648
4 HEMATOLOGIC AGENTS 4,844
13 NEUROLOGIC DRUGS 3,886
19 RESPIRATORY TRACT 2,864
15 OPHTHALMICS 2,217
3 ANTIMICROBIAL AGENTS 1,928
14 ONCOLYTICS 646
12 SKIN/MUCOUS MEMBRANE 604
21 HOMEOPATHIC PRODUCTS 345
1 ANESTHETIC DRUGS 270
16 OTOLOGICS 267




7 CONTRAST MEDIA/ RADIOPHARMACEUTICAL 5
Table 4






1= priority review; 0 
= standard review
ACETAMINOPHEN 4875 1968 1
ASPIRIN 4471 1950 1
FUROSEMIDE 3942 1966 1
LEVOTHYROXINE 2649 2000 0
CALCIUM CARBONATE 2082 2000 0
METOPROLOL 1900 1978 1
LISINOPRIL 1877 1987 0
CITALOPRAM HYDROBRIMIDE 1756 1998 0
DONEPEZIL HCL 1513 1996 1
DIGOXIN 1488 1975 0
WARFARIN SODIUM 1404 1954 0
SERTRALINE 1365 1991 0
RANITIDINE 1337 1977 0
PANTOPRAZOLE SODIUM 1277 2000 0
MIRTAZAPINE 1236 1996 0
AMLODIPINE 1235 1992 0
CLOPIDOGEL 1234 1997 1
HYDROCHLOROTHIAZIDE 1197 1959 1
LANSOPRAZOLE 1187 1995 0
OLANZAPINE 1152 1996 1
RISPERIDONE 1140 1993 1
HYDROCODONE BITARTRATE 1015 1943 0
ALBUTEROL SULFATE 1009 1982 0
ATORVASTATIN CALCIUM 1002 1996 1
OMEPRAZOLE 983 1989 1
ATENOLOL 974 1981 1
LORAZEPAM 957 1977 0
CELECOXIB 933 1998 1
ISOSORBIDE 887 1974 0
QUETIAPINE FUMARATE 854 1997 0
GABAPENTIN 842 1993 1
PAROXETINE HCL 765 1992 0
CARBIDOPA 758 1975 1
IPRATROPIUM BROMIDE 758 1986 1
LEVODOPA 758 1970 1
PHENYTOIN 757 1953 0
VITAMIN E 739 1953 1
FLUTICASONE PROPIONATE 738 1990 0
NITROGLYCERIN 718 1981 1
DILTIAZEM 702 1982 0
Top 40 medications used by 2004 National Nursing Home Survey respondents, ranked 
by number of residents using medication
Table 5Self/private pay/out-of-pocket 67.6%
Medicaid 60.6%
Medicare 13.0%
Private health insurance 7.8%





Sources of payment HEALTHi =  VINTAGEi +  PRIORITY%i +  N_RXi +  Zi + i
Model Regressor Estimate StdErr ChiSq ProbChiSq
1a VINTAGE 0.010 0.002 29.027 0.000
1a PRIORITY% 0.221 0.063 12.185 0.000
1a N_RX 0.016 0.003 23.098 0.000
1b VINTAGE 0.015 0.002 84.198 0.000
1b PRIORITY% 0.230 0.057 16.041 0.000
1b N_RX 0.018 0.003 34.280 0.000
1c VINTAGE 0.011 0.002 48.006 0.000
1c PRIORITY% 0.179 0.057 9.839 0.002
1c N_RX 0.023 0.003 55.646 0.000
1d VINTAGE 0.011 0.002 40.651 0.000
1d PRIORITY% 0.204 0.060 11.606 0.001
1d N_RX 0.037 0.003 126.384 0.000
1e VINTAGE 0.013 0.002 55.714 0.000
1e PRIORITY% 0.193 0.058 10.930 0.001
1e N_RX 0.027 0.003 74.803 0.000
1f VINTAGE 0.012 0.002 45.129 0.000
1f PRIORITY% 0.189 0.061 9.619 0.002
1f N_RX 0.025 0.003 59.045 0.000
VINTAGE = weighted mean vintage (FDA approval year) of medications used
PRIORITY% = fraction of medications used that contained active ingredients approved on 
a priority-review (as opposed to standard-review) basis
N_RX = the total number of medications used 
Table 7
Ordered probit estimates of eq. (1):
N=12,252.  All models include dummy variables for single-year-of-age by sex, race, 
marital status, veteran status, where the resident lived prior to admission, primary 
diagnosis at the time of admission, up to 16 diagnoses at the time of the interview, sources 
of payment, and facility fixed effects.
Dependent variable: Ability to use toilet
Dependent variable: Ability to bathe
Dependent variable: No. of ADLs resident could perform independently
Dependent variable: Ability to transfer
Dependent variable: Ability to dress






included? Regressor Estimate StdErr ChiSq ProbChiSq
1 no no VINTAGE 0.0063 0.0016 15.19 0.0001
1 no no PRIORITY% 0.1651 0.0568 8.45 0.0036
2 yes no VINTAGE 0.0067 0.0016 16.84 0.0000
2 yes no PRIORITY% 0.1767 0.0569 9.65 0.0019
3 no yes VINTAGE 0.0098 0.0018 29.03 0.0000
3 no yes PRIORITY% 0.2208 0.0633 12.18 0.0005
4 no no VINTAGE 0.0113 0.0015 55.06 0.0000
4 no no PRIORITY% 0.2049 0.0530 14.93 0.0001
5 yes no VINTAGE 0.0115 0.0015 56.82 0.0000
5 yes no PRIORITY% 0.2100 0.0531 15.65 0.0001
6 no yes VINTAGE 0.0151 0.0016 84.20 0.0000
6 no yes PRIORITY% 0.2297 0.0573 16.04 0.0001
7 no no VINTAGE 0.0088 0.0015 34.14 0.0000
7 no no PRIORITY% 0.1532 0.0528 8.41 0.0037
8 yes no VINTAGE 0.0091 0.0015 36.13 0.0000
8 yes no PRIORITY% 0.1631 0.0529 9.52 0.0020
9 no yes VINTAGE 0.0114 0.0016 48.01 0.0000
9 no yes PRIORITY% 0.1794 0.0572 9.84 0.0017
Facility characteristics are dummy variables for nursing home ownership type, bedsize, and 
metropolitan area status.
PRIORITY% = fraction of medications used that contained active ingredients approved on a priority-
review (as opposed to standard-review) basis
Estimates of selected coefficients from models with no facility characteristics or fixed effects, 
models with facility characteristics, and models with facility fixed effects
Table 8
Ordered probit estimates of eq. (1):
HEALTHi =  VINTAGEi +  PRIORITY%i +  N_RXi +  Zi + i
Dependent variable: No. of ADLs resident could perform independently
Dependent variable: Ability to transfer
Dependent variable: Ability to dress
N=12,252.  All models include dummy variables for single-year-of-age by sex, race, marital status, 
veteran status, where the resident lived prior to admission, primary diagnosis at the time of 
admission, up to 16 diagnoses at the time of the interview, and sources of payment.








variable Estimate StdErr ChiSq ProbChiSq
10 no no VINTAGE 0.0079 0.0016 25.23 0.0000
10 no no PRIORITY% 0.2055 0.0546 14.17 0.0002
11 yes no VINTAGE 0.0082 0.0016 27.04 0.0000
11 yes no PRIORITY% 0.2139 0.0546 15.33 0.0001
12 no yes VINTAGE 0.0110 0.0017 40.65 0.0000
12 no yes PRIORITY% 0.2038 0.0598 11.61 0.0007
13 no no VINTAGE 0.0095 0.0015 38.51 0.0000
13 no no PRIORITY% 0.1742 0.0537 10.52 0.0012
14 yes no VINTAGE 0.0098 0.0015 40.36 0.0000
14 yes no PRIORITY% 0.1822 0.0538 11.48 0.0007
15 no yes VINTAGE 0.0125 0.0017 55.71 0.0000
15 no yes PRIORITY% 0.1928 0.0583 10.93 0.0009
16 no no VINTAGE 0.0076 0.0016 23.39 0.0000
16 no no PRIORITY% 0.1434 0.0553 6.73 0.0095
17 yes no VINTAGE 0.0079 0.0016 24.80 0.0000
17 yes no PRIORITY% 0.1506 0.0553 7.41 0.0065
18 no yes VINTAGE 0.0117 0.0017 45.13 0.0000
18 no yes PRIORITY% 0.1892 0.0610 9.62 0.0019
PRIORITY% = fraction of medications used that contained active ingredients approved on a priority-
review (as opposed to standard-review) basis
Facility characteristics are dummy variables for nursing home ownership type, bedsize, and 
metropolitan area status.
Ordered probit estimates of eq. (1):
HEALTHi =  VINTAGEi +  PRIORITY%i +  N_RXi +  Zi + i
N=12,252.  All models include dummy variables for single-year-of-age by sex, race, marital status, 
veteran status, where the resident lived prior to admission, primary diagnosis at the time of 
admission, up to 16 diagnoses at the time of the interview, and sources of payment.
VINTAGE = weighted mean vintage (FDA approval year) of medications used
Table 8 (continued)
Estimates of selected coefficients from models with no facility characteristics or fixed effects, 
models with facility characteristics, and models with facility fixed effects
Dependent variable: Ability to eat
Dependent variable: Ability to use toilet
Dependent variable: Ability to batheModel Regressor Estimate StdErr ChiSq ProbChiSq
2a POST1980% 0.181 0.082 4.845 0.028
2a POST1990% 0.341 0.083 17.039 0.000
2a PRIORITY% 0.271 0.063 18.460 0.000
2a N_RX 0.017 0.003 24.847 0.000
2b POST1980% 0.300 0.075 16.046 0.000
2b POST1990% 0.417 0.076 30.473 0.000
2b PRIORITY% 0.276 0.057 23.346 0.000
2b N_RX 0.019 0.003 35.965 0.000
2c POST1980% 0.154 0.075 4.255 0.039
2c POST1990% 0.421 0.075 31.287 0.000
2c PRIORITY% 0.226 0.057 15.676 0.000
2c N_RX 0.024 0.003 58.024 0.000
2d POST1980% 0.207 0.078 7.052 0.008
2d POST1990% 0.417 0.079 28.017 0.000
2d PRIORITY% 0.270 0.060 20.480 0.000
2d N_RX 0.038 0.003 130.147 0.000
2e POST1980% 0.225 0.076 8.716 0.003
2e POST1990% 0.399 0.077 27.009 0.000
2e PRIORITY% 0.242 0.058 17.268 0.000
2e N_RX 0.028 0.003 77.833 0.000
2f POST1980% 0.202 0.080 6.465 0.011
2f POST1990% 0.337 0.080 17.769 0.000
2f PRIORITY% 0.221 0.061 13.187 0.000
2f N_RX 0.026 0.003 60.725 0.000
N=12,252.  All models include dummy variables for single-year-of-age by sex, race, marital status, veteran status, 
where the resident lived prior to admission, primary diagnosis at the time of admission, up to 16 diagnoses at the 
time of the interview, sources of payment, and facility fixed effects.
PRIORITY% = fraction of medications used that contained active ingredients approved on a priority-review (as 
opposed to standard-review) basis
POST1980% = fraction of medications used that contained active ingredients approved after 1980 
POST1990% = fraction of medications used that contained active ingredients approved after 1990
N_RX = the total number of medications used
Table 9
Ordered probit estimates of eq. (2):
Dependent variable: No. of ADLs resident could perform independently
Dependent variable: Ability to transfer
Dependent variable: Ability to dress
Dependent variable: Ability to eat
Dependent variable: Ability to use toilet
Dependent variable: Ability to bathe
HEALTHi = 1 POST1980%i + 2 POST1990%i +  PRIORITY%i +  N_RXi +  Zi + iModel Regressor Estimate StdErr ChiSq ProbChiSq
3a N_RX_NEW 0.047 0.006 70.139 0.000
3a N_RX_OLD -0.005 0.004 1.121 0.290
3a PRIORITY% 0.208 0.061 11.532 0.001
3b N_RX_NEW 0.064 0.005 149.054 0.000
3b N_RX_OLD -0.013 0.004 9.422 0.002
3b PRIORITY% 0.197 0.055 12.571 0.000
3c N_RX_NEW 0.062 0.005 141.171 0.000
3c N_RX_OLD -0.003 0.004 0.491 0.484
3c PRIORITY% 0.170 0.055 9.388 0.002
3d N_RX_NEW 0.077 0.006 187.112 0.000
3d N_RX_OLD 0.011 0.004 6.409 0.011
3d PRIORITY% 0.197 0.058 11.614 0.001
3e N_RX_NEW 0.066 0.005 153.927 0.000
3e N_RX_OLD 0.001 0.004 0.095 0.758
3e PRIORITY% 0.169 0.056 8.980 0.003
3f N_RX_NEW 0.057 0.006 105.978 0.000
3f N_RX_OLD 0.004 0.004 0.787 0.375
3f PRIORITY% 0.153 0.059 6.716 0.010
N=12,252.  All models include dummy variables for single-year-of-age by sex, race, 
marital status, veteran status, where the resident lived prior to admission, primary 
diagnosis at the time of admission, up to 16 diagnoses at the time of the interview, 
sources of payment, and facility fixed effects.
PRIORITY% = fraction of medications used that contained active ingredients approved 
on a priority-review (as opposed to standard-review) basis
N_RX_NEW = the total number of “new” (post-1990) medications used 
N_RX_OLD = the total number of “old” (pre-1991) medications used 
Table 10
Ordered probit estimates of eq. (3):
Dependent variable: No. of ADLs resident could perform independently
Dependent variable: Ability to transfer
Dependent variable: Ability to dress
Dependent variable: Ability to eat
Dependent variable: Ability to use toilet
Dependent variable: Ability to bathe
HEALTHi = 1 N_RX_NEWi + 2 N_RX_OLDi +  PRIORITY%i +  Zi + iModel Regressor Estimate StdErr ChiSq ProbChiSq
1 No. of post-1980 medications 0.0597 0.0054 120.61 0.0000
1 No. of pre-1981 medications -0.0067 0.0061 1.20 0.2733
1 % of meds. that were priority-review 0.2011 0.0613 10.76 0.0010
2 No. of post-1980 medications 0.1443 0.0441 10.70 0.0011
2 No. of pre-1981 medications 0.0083 0.0489 0.03 0.8656
2 % of meds. that were priority-review 0.1512 0.0593 6.49 0.0108
3 No. of post-1980 medications 0.0866 0.0164 27.75 0.0000
3 No. of pre-1981 medications 0.0303 0.0163 3.47 0.0624
3 % of meds. that were priority-review 0.0619 0.0396 2.45 0.1177
4 No. of post-1980 medications 0.0241 0.0342 0.50 0.4807
4 No. of pre-1981 medications -0.0886 0.0394 5.05 0.0246
4 % of meds. that were priority-review 0.0174 0.0486 0.13 0.7201
5 No. of post-1980 medications 0.0476 0.0184 6.71 0.0096
5 No. of pre-1981 medications -0.0016 0.0318 0.00 0.9602
5 % of meds. that were priority-review 0.0132 0.0394 0.11 0.7367
6 No. of post-1980 medications 0.1293 0.0400 10.44 0.0012
6 No. of pre-1981 medications 0.1043 0.0314 11.01 0.0009
6 % of meds. that were priority-review 0.1533 0.0670 5.23 0.0221
Table 11
All models include dummy variables for single-year-of-age by sex, race, marital status, veteran 
status, where the resident lived prior to admission, primary diagnosis at the time of admission, up to 
16 diagnoses at the time of the interview, sources of payment, and facility fixed effects.
Ordered probit estimates of eq. (3), for 5 largest drug classes:
N_INDEP_ADLi = 1 N_POST1980i + 2 N_PRE1981i +  PRIORITY%i +  Zi + i
N_INDEP_ADL = the number of ADLs the resident could perform independently
ALL MEDICATIONS (N = 12,252)
METABOLIC/NUTRIENTS (N = 4546)
CARDIOVASCULAR-RENAL DRUGS (N = 9003)
GASTROINTESTINAL AGENTS (N = 6444)
CENTRAL NERVOUS SYSTEM DRUGS (N = 8539)
RELIEF OF PAIN DRUGS (N = 7253)Activity
average annual rate of decline of functional limitation 




Using the toilet 1.60%
Bathing 1.20%
Table 12






















Transferring Dressing Eating Using the toilet Bathing
Figure 2
Probability of being totally dependent in 2004:
actual vs. predicted if only pre‐1991 medications used
actual
if only pre‐1991 medications used